Chinook Therapeutics, Inc. (KDNY) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Seattle, WA, アメリカ. 現CEOは Eric L. Dobmeier.
KDNY を有する IPO日 2020-10-06, 214 名の正社員, に上場 NASDAQ Global Select, 時価総額 $2.71B.
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a Phase I/II trial for IgA nephropathy; and CHK-336, an oral small molecule LDHA inhibitor for the treatment of primary hyperoxaluria, as well as research programs for other rare and severe chronic kidney diseases. Chinook Therapeutics, Inc. is headquartered in Seattle, Washington.
